While cancer immunotherapies are definitely becoming more de rigeur these days, that doesn’t mean that good old fashioned targeted therapies have been universally abandoned or forgotten, far from it.
Making strategic choices about how to differentiate targeted therapies is never easy
At recent meetings this year, my attention was caught by one target in particular, and despite its chequered history it seems to be making a comeback of sorts thanks to a more focused and tailored approach to therapy.
There is unlikely to be one panacea for everything, but what about going back to basics and matching patients to appropriate therapy based on the underlying biology and what the patiemt’s tumour is telling us? We should have more success doing that theoretically – is that actually the case in practice?
To illustrate this, we have a few examples to share from one particular niche in oncology that readers may find interesting and useful…
To learn more from our latest analysis and get a heads up on our oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.
The potential of Clovis Oncology’s EGFR inhibitor rociletinib (formerly CO-1686) to treat T790M negative non-small cell lung cancer (NSCLC) was one of the interesting talking points of the recent JP Morgan Healthcare conference in San Francisco (JPM15).
At the JP Morgan Healthcare Conference (JPM15), Clovis presented updated data that shows some efficacy in those NSCLC patients who no longer respond to an EGFR inhibitor, but don’t have a T790M mutation (T790M negative). Both AstraZeneca’s competitor compound, AZD9291, and rociletinib shown considerable activity in those EFGR resistant patients who develop a T790M mutation and it’s likely they will both soon be approved in this indication, based on the encouraging data seen to date.
However, what is surprising and could be a key differentiation factor for Clovis, is if there is sufficient efficacy in T790M negative patients for use of the drug in this indication.
In this post, we discuss the potential of rociletinib in NSCLC T790M negative patients, whether thought leaders might use the drug in this indication, and delve deeper into the science behind the efficacy seen.
To learn more about our latest insights, subscribers can log-in or you can purchase access to BSB Premium Content.